Matrine  (Synonyms: Matridin-15-one; Vegard; α-Matrine)

Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI)^{[1][2][3][4][5]}.

Matrine (0-1.5 mg/mL, 24-72 h) inhibits the growth of A549 and SMMC-7721 cells^[1].
Matrine (25 μg/mL, 6 h) suppresses migration of A549 cells^[1].
Matrine (0-1 mg/mL, 48 h) induces apoptosis by reducing the Bcl-2/Bax protein ratios in A549 and SMMC-7721 cells^[1].
Matrine (0-1 mg/mL, 48 h) inhibits miR-182-5p expression and induces the apoptosis of PTC cells^[2].
Matrine (10 μM, 48 h) inhibits cisplatin-induced oxidative injury and inflammation in HK2 cells by reducing ROS level and pro-inflammatory cytokines including IL-1β, IL-6 and TNF-α^[4].
Matrine (10 μM, 48 h) reverses mitochondrial function in cisplatin-induced HK2 cells by activating the SIRT3/OPA1 pathway^[4].
Matrine (0-20 nM, 12 h) promotes HepG2 cell apoptosis by inhibiting mitophagy and PINK1/Parkin pathways^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Matrine (Intragastric administration, 40 and 80 mg/kg for 16 consecutive days, xenograft male C57BL/6mice model) inhibits tumors growth and metastasis without affecting the body weight^[3].
Matrine (Intraperitoneal injections, 5 mg/kg, daily for four continuous days) attenuates renal injury and apoptosis in cisplatin-induced AKI mice, as well as reducing inflammatory responses and activating SIRT3/OPA1 axis and rescues renal mitochondrial dysfunction^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

248.36

C₁₅H₂₄N₂O

519-02-8

Solid

White to off-white

O=C1CCC[C@]2([H])[C@@]3([H])CCCN4[C@@]3([H])[C@](CCC4)([H])CN21

Room temperature in continental US; may vary elsewhere.

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

• [1]. Ying Zhang, et al. Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migration. Cytotechnology. 2009 Apr;59(3):191-200.  [Content Brief]

  [2]. Songbo Fu, et al. Matrine induces papillary thyroid cancer cell apoptosis in vitro and suppresses tumor growth in vivo by downregulating miR-182-5p. Biomed Pharmacother. 2020 Aug;128:110327.  [Content Brief]

  [3]. Bei Zhao, et al. Matrine suppresses lung cancer metastasis via targeting M2-like tumour-associated-macrophages polarization. Am J Cancer Res. 2021 Sep 15;11(9):4308-4328.  [Content Brief]

  [4]. Lu Yuan, et al. Matrine alleviates cisplatin‐induced acute kidney injury by inhibiting mitochondrial dysfunction and inflammation via SIRT3/OPA1 pathway. J Cell Mol Med v.26(13); 2022 Jul.

  [5]. Runjie Wei, et al. Matrine promotes liver cancer cell apoptosis by inhibiting mitophagy and PINK1/Parkin pathways. Cell Stress Chaperones. 2018 Nov;23(6):1295-1309.  [Content Brief]